MESSAGE NO: 4134206 DATE: 05 13 2004
CATEGORY: ADA TYPE: LIQ
REFERENCE: 4043214 REFERENCE DATE: 02 12 2004
CASES: A - 570 - 853 - -
- - - -
- - - -

PERIOD COVERED: 07 06 2000 TO 06 30 2001

LIQ SUSPENSION DATE:

TO: DIRECTORS OF FIELD OPERATIONS
PORT DIRECTORS

FROM: DIRECTOR, SPECIAL ENFORCEMENT

RE: CLARIFICATION OF LIQUIDATION INSTRUCTION 4043214 DATED
02/12/2004 FOR ASPIRING FORM CHINA FOR THE PERIOD OF
07/06/2000 TO 06/30/2001 (A-570-853).

1. ON DECEMBER 30, 2003, THE DEPARTMENT OF COMMERCE
("DEPARTMENT" ) PUBLISHED A NOTICE OF AMENDED FINAL DETERMINATION
AND AMENDED ORDER PURSUANT TO FINAL COURT DECISION (68 FR 75208).
ON AUGUST 13, 2003, THE DEPARTMENT PUBLISHED A NOTICE OF FINAL
RESULTS OF ANTIDUMPING DUTY REVIEW (68 FR 48337). THIS IS A
CLARIFICATION OF MESSAGE 4043214 DATED FEBRUARY 12, 2004 AT
PARAGRAPH 2.

2. THESE INSTRUCTIONS CLARIFY PARAGRAPH 2 OF MESSAGE 4043214 BY
SPECIFYING THE IMPORTER NAME. FOR ALL SHIPMENTS OF BULK ASPIRIN
FROM THE PEOPLE'S REPUBLIC OF CHINA PRODUCED AND EXPORTED BY
JILIN HENGHE PHARMACEUTICAL CO. ("JILIN") OR SHANDONG XINHUA
PHARMACEUTICAL CO., LTD. ("SHANDONG"), WHERE JILIN OR SHANDONG
CAN DEMONSTRATE THAT ITS U.S. SALES AFFILIATE LISTED BELOW (I.E.,
JILIN PHARMACEUTICAL (U.S.A.), INC. OR SHANDONG-XHINHUA EASTWEST
INC.) WAS THE IMPORTER AND THE CUSTOMER WAS A CUSTOMER NAMED IN
PARAGRAPH 2 OF MESSAGE 4043214, LIQUIDATE AT THE APPLICABLE
CUSTOMER RATE STATED IN MESSAGE 4043214.

MANUFACTURER: JILIN HENGHE PHARMACEUTICAL CO.
(A-570-853-001)
U.S. SALES AFFILIATE: JILIN PHARMACEUTICAL (U.S.A.), INC.

MANUFACTURER: SHANDONG XINHUA PHARMACEUTICAL CO., LTD.
(A-570-853-002)
U.S. SALES AFFILIATE: SHANDONG-XINHUA EASTWEST INC.

3. IF THERE ARE ANY QUESTIONS REGARDING THIS MATTER BY CUSTOMS
OFFICERS, THE IMPORTING PUBLIC, OR INTERESTED PARTIES PLEASE
CONTACT DAVINA HASHMI AT OFFICE OF AD/CVD ENFORCEMENT, IMPORT
ADMINISTRATION, INTERNATIONAL TRADE ADMINISTRATION, U.S.
DEPARTMENT OF COMMERCE AT (202) 482-0984 (GENERATED BY G1O1:JS).

4. THERE ARE NO RESTRICTIONS ON THE RELEASE OF THIS INFORMATION.

CATHY SAUCEDA